Down-regulation of X-linked inhibitor of apoptosis protein induces apoptosis in chemoresistant human ovarian cancer cells.

Cisplatin-centered chemotherapy is a key treatment for ovarian cancer, but resistance to chemotherapeutic agents remains a major cause of treatment failure. Multiple factors are known to contribute to the development of this chemoresistance. Although it has been demonstrated that X-linked inhibitor of apoptosis protein (Xiap) prevents apoptosis by inhibiting effector caspases, if and how it is important in chemoresistance in ovarian cancer has not been studied. The effects of Xiap down-regulation and/or restoration of wild type p53 by recombinant adenovirus infection were examined on four ovarian epithelial cancer cell lines [C13*, A2780-s (wild type p53), A2780-cp (mutant p53), and SKOV3 (null p53)]. Apoptosis and protein expression (e.g., Xiap, caspase-3, p53, MDM2, and p21waf1) were assessed by Hoechst 33258 stain and Western blot, respectively. We demonstrated that Xiap down-regulation following adenoviral antisense expression induces apoptosis in the wild-type p53 cells, but not in the mutated or null cells. Xiap down-regulation resulted in caspase-3 activation, caspase-mediated MDM2 processing, and p53 accumulation. Restoration of wild type p53 in the p53-mutated or -null cells significantly enhanced the proapoptotic effect of Xiap antisense expression. Down-regulation of Xiap induced apoptosis in chemoresistant ovarian cancer cells, a process dependent on p53 status.

[1]  Jiandong Chen,et al.  Activation of an MDM2-specific Caspase by p53 in the Absence of Apoptosis* , 1999, The Journal of Biological Chemistry.

[2]  J. M. Kim,et al.  Involvement of the Fas/fas Ligand System in P53- Mediated Granulosa Cell Apoptosis during Follicular Development and Atresia* , 2022 .

[3]  Jiandong Chen,et al.  A 60 kd MDM2 isoform is produced by caspase cleavage in non-apoptotic tumor cells , 1998, Oncogene.

[4]  G. Sirugo,et al.  Induction of Apoptosis and Inhibition of Cell Proliferation bysurvivin Gene Targeting* , 1998, The Journal of Biological Chemistry.

[5]  D. Altieri,et al.  Expression of a novel antiapoptosis gene, survivin, correlated with tumor cell apoptosis and p53 accumulation in gastric carcinomas. , 1998, Cancer research.

[6]  J C Reed,et al.  IAPs block apoptotic events induced by caspase‐8 and cytochrome c by direct inhibition of distinct caspases , 1998, The EMBO journal.

[7]  J C Reed,et al.  A Single BIR Domain of XIAP Sufficient for Inhibiting Caspases* , 1998, The Journal of Biological Chemistry.

[8]  C. Widmann,et al.  Caspase-dependent Cleavage of Signaling Proteins during Apoptosis , 1998, The Journal of Biological Chemistry.

[9]  Hirofumi Tanaka,et al.  Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53 , 1997, FEBS letters.

[10]  A. Levine,et al.  Proteolytic Cleavage of the mdm2 Oncoprotein during Apoptosis* , 1997, The Journal of Biological Chemistry.

[11]  J. Schellens,et al.  Cisplatin resistance and DNA repair. , 1997, Cancer Treatment Reviews.

[12]  D. Altieri,et al.  A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma , 1997, Nature Medicine.

[13]  Guy S. Salvesen,et al.  X-linked IAP is a direct inhibitor of cell-death proteases , 1997, Nature.

[14]  G. Cooper,et al.  Identification of the MDM2 Oncoprotein as a Substrate for CPP32-like Apoptotic Proteases* , 1997, The Journal of Biological Chemistry.

[15]  R. Gibb,et al.  Apoptosis as a measure of chemosensitivity to cisplatin and taxol therapy in ovarian cancer cell lines. , 1997, Gynecologic oncology.

[16]  S. Chaney,et al.  DNA damage inducible-gene expression following platinum treatment in human ovarian carcinoma cell lines , 1996, Cancer Chemotherapy and Pharmacology.

[17]  T. Tsuruo,et al.  Activation of actin-cleavable interleukin 1beta-converting enzyme (ICE) family protease CPP-32 during chemotherapeutic agent-induced apoptosis in ovarian carcinoma cells. , 1996, Cancer research.

[18]  C. Thompson,et al.  A conserved family of cellular genes related to the baculovirus iap gene and encoding apoptosis inhibitors. , 1996, The EMBO journal.

[19]  D. Vaux,et al.  Cloning and expression of apoptosis inhibitory protein homologs that function to inhibit apoptosis and/or bind tumor necrosis factor receptor-associated factors. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[20]  S. Nagata,et al.  Sequential activation of ICE-like and CPP32-like proteases during Fas-mediated apoptosis , 1996, Nature.

[21]  J C Reed,et al.  Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems. , 1996, Cancer research.

[22]  K. Tamai,et al.  Suppression of apoptosis in mammalian cells by NAIP and a related family of IAP genes , 1996, Nature.

[23]  Mike Rothe,et al.  The TNFR2-TRAF signaling complex contains two novel proteins related to baculoviral inhibitor of apoptosis proteins , 1995, Cell.

[24]  M. Janicek,et al.  Combination anti-gene therapy targeting c-myc and p53 in ovarian cancer cell lines. , 1995, Gynecologic oncology.

[25]  T. Crawford,et al.  The gene for neuronal apoptosis inhibitory protein is partially deleted in individuals with spinal muscular atrophy , 1995, Cell.

[26]  W. Kaufmann,et al.  Enhanced replicative bypass of platinum-DNA adducts in cisplatin-resistant human ovarian carcinoma cell lines. , 1994, Cancer research.

[27]  P. Burns,et al.  Increased accumulation of p53 protein in cisplatin‐resistant ovarian cell lines , 1993, International journal of cancer.

[28]  A. Levine,et al.  The p53-mdm-2 autoregulatory feedback loop. , 1993, Genes & development.

[29]  M. Oren,et al.  mdm2 expression is induced by wild type p53 activity. , 1993, The EMBO journal.

[30]  A. Levine,et al.  The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation , 1992, Cell.

[31]  B. Vogelstein,et al.  p53 mutations in human cancers. , 1991, Science.

[32]  A. Pa,et al.  Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance. , 1990 .

[33]  P. Seth,et al.  Sensitization of cis-platinum by a recombinant adenovirus vector expressing wild-type p53 gene in human ovarian carcinomas. , 1997, Oncology research.

[34]  S. Howell,et al.  Rapid emergence of acquired cis-diamminedichloroplatinum(II) resistance in an in vivo model of human ovarian carcinoma. , 1990, Cancer communications.

[35]  S. Howell,et al.  Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance. , 1990, Cancer cells.

[36]  S. Howell,et al.  Enhanced potentiation of cisplatin cytotoxicity in human ovarian carcinoma cells by prolonged glutathione depletion. , 1988, Chemico-biological interactions.

[37]  S. Howell,et al.  cis-Diamminedichloroplatinum(II) accumulation in sensitive and resistant human ovarian carcinoma cells. , 1988, Cancer research.